Business Wire

Leading Pharmaceutical Company Selects Kinaxis to Cure Supply Chain Headaches

Share

Kinaxis® Inc. (TSX: KXS), a global leader in end-to-end supply chain orchestration, today announced that Servier, a global independent pharmaceutical group, has selected Kinaxis to help revolutionize its supply chain planning capabilities with a view to accelerating time to market for its portfolio of life-saving drugs.

One of the world’s preeminent pharmaceutical companies, Servier has nearly 22,000 employees and a presence in 150 countries, with medicines targeting cancers, diabetes, as well as immune-inflammatory, neuropsychiatric, cardiovascular, and venous diseases. The company’s unique status as a laboratory governed by a non-profit foundation sees it invest upwards of 20% of its revenue each year from brand-name medicines into research and development, a strategy that has enabled it to accelerate research to discover new treatments faster for the benefits of patients.

As part of the deployment, Kinaxis will enable Servier to plan more effectively and gain critical end-to-end visibility of its overall supply chain; a vital requirement as competing jurisdictional regulations, demand variability, and increased global disruptions play havoc with the pharmaceutical industry’s mission to deliver high-quality products to customers at the lowest cost and with the shortest lead time.

“One of Servier’s principal ambitions is to be a resilient, growing, and sustainable company that’s focused on a few areas where we can make the greatest impact globally for patients,” said Xavier Morelon, head of supply chain at Servier. “To do so, we know we should rely on best-in-class partners like Kinaxis which are so critical to helping us become more agile and ensuring our supply chain can enable us to hit this lofty objective.”

“From making sure patients have the right medications when they need them to keeping up with regulations, expiry dates, and patent cliffs, no industry can compare to life sciences when it comes to complexity,” said Fabienne Cetre, regional vice president, Central Europe at Kinaxis. “We’re thrilled to be working with Servier and are confident our deep industry expertise will enable everyone from their C-suite to their planners and analysts to see more clearly through these challenges so that they can focus on what they do best – delivering products to help people live longer and healthier lives.”

With the addition of France’s second largest pharmaceutical company to its growing customer base, Kinaxis continues to cement its leadership within the life sciences industry, which provides the brand-name and generic medicines that countless patients rely on.

Kinaxis’ AI-powered software allows companies to orchestrate their supply chain network end to end, from strategic planning to last-mile delivery. Kinaxis’ technology helps companies that supply the agricultural industry with 40% of the world’s tractors, that keep more than 110 billion teeth clean each year, and that ensures more than 35 million pets are fed nutritious meals each year.

To learn more about Kinaxis and its supply chain management solutions, please visit Kinaxis.com.

About Kinaxis

Kinaxis is a global leader in modern supply chain orchestration. We serve supply chains and the people who manage them in service of humanity. Our software is trusted by renowned global brands to provide the agility and predictability needed to navigate today’s volatility and disruption. We combine our patented concurrency technique with a human-centered approach to AI to empower businesses of all sizes to manage their end-to-end supply chain network, from multi-year strategic planning through down-to-the-second execution and last-mile delivery. For more news and information, please visit kinaxis.com or follow us on LinkedIn.

About Servier

Founded to serve health, Servier is a global pharmaceutical group governed by a Foundation that aspires to have a meaningful social impact, both for patients and for a sustainable world. With its unique governance model, it can fully serve its vocation with a long-term vision: being committed to therapeutic progress to serve patient needs. The 21,900 employees of the Group are committed to this shared vocation, a source of inspiration every day.

As a world leader in cardiology, Servier’s ambition is to become a focused and innovative player in oncology by targeting hard-to treat cancers. That is why the Group allocates over 70% of its R&D budget to developing targeted and innovative therapies in oncology. Neuroscience and immuno-inflammatory diseases are the future growth drivers.

In these areas, Servier is focused on a limited number of diseases in which accurate patient profiling makes it possible to offer a targeted therapeutic response through precision medicine. To promote access to quality care for all at a lower cost, the Group also offers a range of quality generic drugs covering most pathologies, relying on strong brands in France, Eastern Europe, Brazil and Nigeria.

In all these areas, the Group includes the patient voice at each stage of the life cycle of a medicine. Headquartered in France, Servier relies on a strong geographical footprint in over 150 countries and achieved a revenue of €5.3 billion in 2023.

More information on the new Group website: servier.com

Follow us on social media: LinkedIn, Facebook, Twitter, Instagram

Source: Kinaxis

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Media Relations
Jaime Cook | Kinaxis
jcook@kinaxis.com
289-552-4640

Investor Relations
Rick Wadsworth | Kinaxis
rwadsworth@kinaxis.com
613-907-7613

Servier:
presse@servier.com

About Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Negative Emotions High Across Countries in Conflict in Greater Europe25.6.2024 06:01:00 CEST | Press release

In 2023, Ukraine was engulfed in war, while a new clash erupted between Israel and Hamas in the European sphere of influence. The Gallup Global Emotions 2024 report reveals the emotional toll of these conflicts. The report offers a snapshot of Gallup’s latest measurements of people’s positive and negative daily experiences. The findings are based on nearly 146,000 interviews with adults in 142 countries and areas in 2023. While global negative emotions dipped for the first time in a decade and positive emotions rebounded to their pre-pandemic highs, many of the world’s conflict zones remained bleak. After Oct. 7 Attacks, Israel Vaulted to Top 10 in Negative Emotions Israel, surveyed by Gallup two weeks after the Oct. 7 Hamas attacks, made the top 10 list of countries with the worst Negative Experience Index scores for the first time, at 47. In 2022, Israel ranked among the countries with the lowest scores in the world on this index. Fueling this low score, Israelis saw massive increase

DNP Achieved Over 85% Repulpability for High Barrier Paper Mono-Material Sheet25.6.2024 03:00:00 CEST | Press release

Dai Nippon Printing Co., Ltd. (DNP, TOKYO:7912) has successfully updated the materials and processing methods used in a proprietary mono-material sheet for packaging product to achieve over 85% repulpability1. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240620532988/en/ Image of updated packaging employing paper mono-material sheet (Photo: Business Wire) In 2022 we developed an environmentally friendly packaging sheet with high barrier properties2 that prevents the transmission of oxygen and water vapor as packaging materials for food, cosmetics, and medical products. At the same time, the use of mono-material paper facilitated increased recyclability. Development In recent years, as an indicator of eco-friendliness in the recyclability of paper packaging, efforts have been witnessed in Europe and the United States to improve the recycling effect of paper as a renewable resource, by increasing the repulpability to more th

China Hi-Tech Fair Gearing up for Its 26th Edition on November 14 in Shenzhen25.6.2024 02:00:00 CEST | Press release

China Hi-Tech Fair (CHTF), a large-scale international event and China's premier tech show showcasing innovative technologies and products, will kick off its 26th edition on November 14-16, 2024 at Shenzhen World Exhibition & Convention Center under the theme "Technology Leads Development, Industry Integrates Fusion". Covering an exhibition area of 400,000m2, CHTF 2024 is expected to attract over 5,000 exhibitors and 500,000 attendees from more than 100 countries and regions. This year, the event will feature 20 top fast-growing sectors, including China’s Leading Heavy Equipment, Top Tech Industry Chains, Clean Energy, High-end Machinery Manufacturing and Low-altitude Economy & Aerospace, etc. About 150 activities will be held concurrently. Leveraging Shenzhen's role as an international innovation center, CHTF has become an important gateway for China's high-tech sector to connect with the international community, and a top-level platform empowering tech companies to elevate their glob

Merck Provides Update on Phase III TrilynX Study in Locally Advanced Head and Neck Cancer24.6.2024 22:35:00 CEST | Press release

Merck, a leading science and technology company, today announced the discontinuation of the Phase III randomized TrilynX study evaluating xevinapant plus chemoradiotherapy (CRT) in patients with unresected locally advanced squamous cell carcinoma of the head and neck (LA SCCHN). The decision follows a pre-planned interim analysis performed by the study’s Independent Data Monitoring Committee, which found that the trial would be unlikely to meet its primary objective of prolonging event-free survival. Top-line safety data were overall compatible with the chemo-radio sensitizing properties of xevinapant. The company will conduct an in-depth review of the data and will share the results in a peer-reviewed forum. LA SCCHN has proven to be a difficult-to-treat form of cancer. CRT has remained the standard of care for decades, despite multiple studies designed to improve outcomes with new treatment approaches, including multiple immunotherapy trials. “We sincerely thank the patients, caregiv

Verimatrix To Showcase Mobile App Protection Platform at OWASP Events in Lisbon and San Francisco24.6.2024 17:45:00 CEST | Press release

Regulatory News: Verimatrix, (Euronext Paris: VMX, FR0010291245), the leader in powering the modern connected world with people-centered security, today announced its participation in two leading events organized by the Open Worldwide Application Security Project (OWASP). The following conferences will showcase the award-winning Verimatrix Extended Threat Defense (XTD) mobile app security solutions: OWASP Global AppSec Lisbon 2024 – June 24-28, 2024 Lisbon Congress Centre – Lisbon, Portugal https://lisbon.globalappsec.org/ OWASP Global AppSec San Francisco 2024 – September 23-27, 2024 Hyatt Regency San Francisco – San Francisco, California https://sf.globalappsec.org/ Bringing together those tasked with ensuring proper security for apps, the associated enterprise, as well as their app users, OWASP events serve as leading venues to illustrate the value and differentiation that comes with proactively deploying mobile app protections. Verimatrix XTD mobile app security solutions quickly a

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
HiddenA line styled icon from Orion Icon Library.Eye